NCT02064309View on ClinicalTrials.gov

An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Long-standing Type 1 Diabetes Mellitus
Interventions
DEVICE

Beta-Air device for encapsulation of transplanted human islets

Trial Locations (1)

SE-75123

Uppsala University Hospital, Uppsala

Sponsors

Collaborators (1)

Beta-O2 Technologies Ltd.
All Listed Sponsors
collaborator

Beta-O2 Technologies Ltd.

INDUSTRY

lead

Uppsala University Hospital

OTHER

NCT02064309 - An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter